Virtual Meetings 2021

Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal Cancers

For more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.

PARTICIPATING FACULTY

Professor Dirk Arnold, MD, PhD
Director
Asklepios Tumorzentrum Hamburg
Asklepios Klinik Altona
Hamburg, Germany

Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center (AZ, FL and MN)
Consultant, Mayo Clinic in Arizona
Phoenix, Arizona

Johanna Bendell, MD
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Daniel Catenacci, MD
Associate Professor, Department of Medicine
Section of Hematology and Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research
Comprehensive Cancer Center
The University of Chicago Medical Center and Biological Sciences
Chicago, Illinois

Axel Grothey, MD
Director, GI Cancer Research
West Cancer Center and Research Institute
Medical Director
OneOncology Research Network
Germantown, Tennessee



Wells A Messersmith, MD
Professor and Head, Division of Medical Oncology
Associate Director for Translational Research
University of Colorado Cancer Center
Aurora, Colorado

Eileen M O’Reilly, MD
Winthrop Rockefeller Endowed Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers
Co-Director, Medical Initiatives
David M Rubenstein Center for Pancreatic Cancer Research
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Philip Agop Philip, MD, PhD, FRCP
Professor of Oncology and Pharmacology
Leader, GI and Neuroendocrine Oncology
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Alan P Venook, MD
The Madden Family Distinguished Professor of
Medical Oncology and Translational Research
Shorenstein Associate Director, Program Development
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Zev Wainberg, MD, MSc
Associate Professor, Department of Medicine
Director, Early Phase Clinical Research Support
Co-Director, UCLA GI Oncology Program
Jonsson Comprehensive Cancer Center
Los Angeles, California


SERIES MODERATOR
Neil Love, MD
Research To Practice

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for gastrointestinal cancers. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Selection and Sequencing of Therapy for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

    MODULE 2: Evidence-Based Management of Advanced Hepatocellular Carcinoma

    MODULE 3: Optimizing Personalized Treatment for Metastatic Colorectal Cancer

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal cancers.

Learning Objectives

  • Evaluate recently presented clinical research findings applicable to the optimal selection and sequencing of systemic therapy for patients with advanced colorectal cancer (CRC), gastric/gastroesophageal cancer (GC) and hepatocellular carcinoma (HCC), and consider how these data sets affect current clinical decision-making.
  • Develop a long-term care plan for patients diagnosed with metastatic CRC, considering biomarker profile (eg, BRAF, microsatellite instability status), tumor location, prior systemic therapy, symptomatology, performance status and personal goals of treatment.
  • Assess biomarker test results (eg, HER2, PD-L1 status), clinical factors and patient preferences to optimize the selection and sequence of systemic therapy for locally advanced or metastatic GC.
  • Use patient age, performance status, degree of liver function and other clinical factors to individualize therapeutic recommendations for newly diagnosed and relapsed/refractory unresectable or metastatic HCC.
  • Appreciate the clinical prevalence and significance of elevated AFP (alpha-fetoprotein) expression in patients with advanced HCC, evaluate available data documenting the benefit of specific management approaches for patients with high AFP levels and personalize therapeutic recommendations.
  • Evaluate the rationale for and appropriateness of specific adaptations to cancer management and follow-up practices for patients with CRC, GC and HCC to account for the realities of the COVID-19 pandemic, and implement or suggest relevant changes within your practice.
  • Appraise available and emerging data with investigational agents and strategies currently in clinical testing for CRC, GC and HCC, and where applicable, refer eligible patients for clinical trial participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by an educational grant from Lilly.